Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Progen enrolls first patient in phase II trial of PI-88 in multiple myeloma

Jan. 24, 2002

Survival data announced from phase II trial of GD-0039 in metastatic renal cancer

Jan. 23, 2002

Arius postpones murine ARH460-23 antibody development

Jan. 22, 2002

Initiation of phase III trial of Ceplene/IL-2 in metastatic melanoma with liver metastases

Jan. 21, 2002

Interferon Sciences explores cancer indications for Alferon N Injection

Jan. 16, 2002

High-dose HspE7 effective and well tolerated in high-grade anal dysplasia

Jan. 14, 2002

Interim analysis of first phase III Provenge trial inconclusive

Jan. 14, 2002

Ceplene plus IL-2 prolongs survival in subset of metastatic melanoma patients

Jan. 14, 2002

Medarex's tumor vaccine program to evaluate melanoma vaccines in conjunction with MDX-010

Jan. 11, 2002

Transgene's Ad-IFNgamma product candidate enters phase I trial for cutaneous lymphoma

Jan. 11, 2002

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...